Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

— Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study — — RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies in Pregnant Women — — RLYB212 Phase 2 Study Expected To Commence in 2H 2024 — NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) … [Read more…]

Toyoda Gosei Invests in ThinkCyte, a Startup Developing Devices for the Early Detection of Leukemia and Other Diseases

KIYOSU, Japan–(BUSINESS WIRE)–Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested* in ThinkCyte K.K., whose technologies are used for a broad spectrum of applications, including the early detection of leukemia and other diseases, with the aim of solving social issues in the healthcare field. ThinkCyte is a startup developing and commercializing cell analysis and sorting technology platform … [Read more…]

AHF Calls for China’s Full Transparency on Spike in Respiratory Illnesses

LOS ANGELES–(BUSINESS WIRE)–#COVID19–Following the Associated Press reporting that the World Health Organization requested that China provide more data on a “potentially worrying spike in respiratory illnesses and clusters of pneumonia in children” publicly, AIDS Healthcare Foundation expresses concern today and urges China to be transparent and cooperate with the WHO unequivocally. “China has a history … [Read more…]

SignalFire Announces Strategic Growth with the Addition of Nine New Team Members

The firm is strengthening the team with new hires and promotions, deepening the commitment to helping innovative founders grow their businesses SAN FRANCISCO–(BUSINESS WIRE)–SignalFire, a tech-enabled early-stage venture capital firm harnessing data and artificial intelligence at scale to identify investments and support the next generation of startups, has announced the firm has hired nine new … [Read more…]

Global Cell Therapy Raw Materials Market Size, Share & Trends Analysis Report 2023-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Raw Materials Market 2023 – 2030” report has been added to ResearchAndMarkets.com’s offering. The global cell therapy raw materials market size is anticipated to reach USD 19.77 billion by 2030. The market is projected to grow at a CAGR of 24.47% The rising investments in the research and development of various … [Read more…]

Paige and Nuance Collaborate to Establish the Largest Consultation Network in Pathology

Paige will leverage the Nuance PowerShare image sharing network for expert second opinions in pathology NEW YORK–(BUSINESS WIRE)–At the Radiological Society of North America’s (RSNA) 109th Scientific Assembly and Annual Meeting, Paige, a global leader in end-to-end digital pathology solutions and clinical AI applications that assist in diagnosing cancer, announced it has teamed up with … [Read more…]

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy European Medicines Agency (EMA) validates regulatory application for epcoritamab for the same indication The regulatory actions are supported by data from the phase … [Read more…]

Revvity Launches EONIS Q System Enabling Faster, Simplified Newborn Screening for SMA and SCID

Innovative, easy-to-use molecular diagnostics workflow reduces complexity and costs for labs looking to expand newborn screening capabilities WALTHAM, Mass.–(BUSINESS WIRE)–Today, Revvity, Inc., announced the launch of its EONIS™ Q system, a CE-IVD declared platform enabling laboratories in countries that accept the CE marking to adopt molecular testing for spinal muscular atrophy (SMA) and severe combined … [Read more…]

Innate Pharma to Host Virtual KOL Event on Lacutamab

The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome which have been selected for oral presentation at the American Society of Hematology (ASH) Annual Meeting Virtual KOL event will be held on Tuesday, December 12, 2023 at 7:00AM PST (4:00PM … [Read more…]

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

A single dose of measles and rubella (MR) vaccine delivered to adults by the Vaxxas high-density microarray patch (HD-MAP) provided antibody responses comparable to the same vaccine delivered by needle and syringe. Higher antibody responses in study participants with the lowest levels of pre-existing antibodies to MR; providing a solid foundation for an upcoming trial … [Read more…]